Information about Lybocent
My details
*
*
*

Lybocent (SRL)

BE

0802.581.859

Company information

Status
Active

Enterprise number

BE0802.581.859

VAT liability
Yes
Established
09-06-2023
Last balance sheet year
2025
Company size
Micro 0 FTE
Legal form
Société à responsabilité limitée (SRL)
Commercial name
Alvo Verso
Principal activity
Non-specialised retail sale of predominately food, beverages or tobacco
Health barometer
Credit limit
Detailpage

Are you looking for more information about this company?

  • Consult health at a glance

  • Choose quick insights or granular details

  • Get updates on important developments

Try for free Discover more

7-day free trial, no credit card required.

Financial data from Lybocent

2025 2024
Income statement
Profit/Loss € 8,259 49% € 5,543
Gross margin € 12,557 63% € 7,714
Balance sheet
Balance sheet total € 83,274 436% € 15,551
Equity € 18,802 78% € 10,543
Debts € 64,472 > 1000% € 5,008

Publications from Lybocent

Date Publication
28-08-2026 Articles of Association (Translation, Coordination, Other Modifications, …) - Registered Office - Goal (NL)
13-06-2023 Rubric Constitution (New Juridical Person, Opening Branch, etc...) (NL)

Frequently asked questions

What is the VAT number of Lybocent?
The VAT number of Lybocent is BE 0802.581.859.
Wat is the PEPPOL ID of Lybocent?
The PEPPOL ID of Lybocent is 0208:0802581859. Log in or start a free trial to see the full overview.
When was Lybocent founded?
Lybocent was founded on 09-06-2023.
What is the address of Lybocent?
The current registered office of Lybocent is located at Hundelgemsesteenweg 27, 9050 Gent.
When was the last time Lybocent filed their annual financial statements?
The most recent financial statements of Lybocent were filed on 05-02-2026.
How many employees does Lybocent have?
There are currently no employees working at Lybocent or no workforce information is available.
What is the annual turnover of Lybocent?
At the time of its most recent financial statements, Lybocent did not publish any turnover figures. Lybocent reported a gross margin of €12,557.44.

Sources